Related Experiment Videos
Anti-CD23
Lanny J Rosenwasser1, Jianfeng Meng
1Division of Allergy and Immunology, Department of Medicine, National Jewish Medical and Research Center/University of Colorado Health Sciences Center, Denver, CO, USA. rosenwasserl@njc.org
Clinical Reviews in Allergy & Immunology
|October 14, 2005
Summary
Targeting CD23, a key receptor in allergic responses, with Lumiliximab shows promise. This anti-CD23 monoclonal antibody was well-tolerated in a phase I trial for allergic asthma, reducing IgE levels.
Area of Science:
- Immunology
- Allergology
- Pharmacology
Background:
- CD23, the low-affinity IgE receptor, is crucial in IgE-mediated immune responses and allergic diseases.
- Both membrane-bound and soluble CD23 play significant roles in allergic reactions.
- Expression of CD23 is linked to the development of allergic conditions.
Purpose of the Study:
- To evaluate the safety and tolerability of Lumiliximab, an anti-CD23 monoclonal antibody, in patients with allergic asthma.
- To assess the impact of Lumiliximab on total IgE levels and its pharmacokinetic profile.
Main Methods:
- A phase I, placebo-controlled clinical trial was conducted with allergic asthma patients.
- Lumiliximab was administered at various doses, and adverse events were monitored.
- Serum total IgE concentrations and Lumiliximab serum half-life were measured.
Main Results:
- Lumiliximab was well-tolerated with mild adverse events, unrelated to dosage.
- Dose-dependent reductions in mean serum total IgE concentrations were observed.
- The serum half-life of Lumiliximab increased with higher doses.
Conclusions:
- Anti-CD23 therapy, exemplified by Lumiliximab, is a promising candidate for allergic diseases.
- Further confirmation of safety and efficacy in allergic asthma and rhinitis is warranted.
- Potential mechanisms include blocking antigen presentation and reducing pro-inflammatory mediators.